Climb Bio reports Q4/FY2024 results, cash $212.5M through 2027; launches $22.35M ATM offering

Climb Bio, Inc.

Entered ATM equity offering of up to $22.35M via Oppenheimer; 3% commission; proceeds to support pipeline.
Cash, equivalents and marketable securities $212.5M at year-end; expected to fund operations through 2027.
Net loss $73.9M for FY2024 includes $51.7M in-process R&D from Tenet acquisition; Q4 net loss $8.4M.
FDA cleared Phase 2 trial for budoprutug in pMN and Phase 1b/2a in ITP; dosing starts H1/H2 2025.
In-licensed CLYM116 (anti-APRIL) for IgAN; IND-enabling; preclinical data H2 2025; new CBO Perrin Wilson.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.